Trial · NCT02578914
A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
NCT02578914, Phase 2, Completed, Aldeyra Therapeutics, Inc.; results first posted 2023-12-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis. Trials, record NCT02578914. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02578914
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
- NCT number
- NCT02578914
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 100 participants, actual
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Conditions
- Allergic Conjunctivitis, Seasonal Allergies
- Interventions
- NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%)
- First posted
- 2015-10-19
- Last updated
- 2023-12-05
- Results first posted
- 2023-12-05
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge | The efficacy assessment period was assessed at Day 14; baseline was Day -7. | Mean change from baseline in ocular itching score using a 0 to 4 scale (0 = none, 4 = severe) on Day 14, 60 minutes into the allergen challenge. The least squares mean (standard error) was derived from analysis of covariance (ANCOVA) with baseline as a covariate and treatment group as a factor. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge | The efficacy assessment period was assessed at Day 14; baseline was Day -7. | Intent-to-treat population | units on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge | NS2 Ophthalmic Drops (0.5%) | -1.550 | Standard Error 0.168 | units on a scale | |
| Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge | Vehicle Ophthalmic Drops | -1.013 | Standard Error 0.163 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | NS2 Ophthalmic Drops (0.5%) | 50 | |
| Overall Study | STARTED | Vehicle Ophthalmic Drops | 50 | |
| Overall Study | COMPLETED | NS2 Ophthalmic Drops (0.5%) | 48 | |
| Overall Study | COMPLETED | Vehicle Ophthalmic Drops | 50 | |
| Overall Study | NOT COMPLETED | NS2 Ophthalmic Drops (0.5%) | 2 | |
| Overall Study | NOT COMPLETED | Vehicle Ophthalmic Drops | 0 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | General disorders and administration site conditions | General disorders | NS2 Ophthalmic Drops (0.5%) | 49 | 50 | |
| other | General disorders and administration site conditions | General disorders | Vehicle Ophthalmic Drops | 4 | 50 | |
| other | Lacrimination increased | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 3 | 50 | |
| other | Lacrimination increased | Eye disorders | Vehicle Ophthalmic Drops | 0 | 50 | |
| other | Punctate keratitis | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 3 | 50 | |
| other | Punctate keratitis | Eye disorders | Vehicle Ophthalmic Drops | 2 | 50 | |
| other | Headache | Nervous system disorders | NS2 Ophthalmic Drops (0.5%) | 6 | 50 | |
| other | Headache | Nervous system disorders | Vehicle Ophthalmic Drops | 5 | 50 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | NS2 Ophthalmic Drops (0.5%) | 0 | 50 |
| Total, all-cause mortality | Vehicle Ophthalmic Drops | 0 | 50 |
| Total, other adverse events | NS2 Ophthalmic Drops (0.5%) | 49 | 50 |
| Total, other adverse events | Vehicle Ophthalmic Drops | 11 | 50 |
| Total, serious adverse events | NS2 Ophthalmic Drops (0.5%) | 0 | 50 |
| Total, serious adverse events | Vehicle Ophthalmic Drops | 0 | 50 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| NS2 Ophthalmic Drops (0.5%) vs Vehicle Ophthalmic Drops: deaths from any cause | Trial comparisons |
| NS2 Ophthalmic Drops (0.5%) vs Vehicle Ophthalmic Drops: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02578914
GET https://conductscience.org/api/trials/v1/NCT02578914/registered